Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CDK1 | P06493 | 6/20 | 0.55 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | CDK9 | P50750 | 3/20 | 0.55 |
| ▸ | CDK4 | P11802 | 2/20 | 0.55 |
| ▸ | CDK7 | P50613 | 2/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNH | P51946 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.55 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.54 |
| ▸ | STK16 | O75716 | 2/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.54 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062164 | 0.91 | NTRK1 (0.63) | CA2CA1CA9CDK1KDR | |
| SCHEMBL4065851 | 0.85 | SYK (0.55) | CA2CA1CA9CDK1KDR | |
| SCHEMBL13898290 | 0.84 | IGF1R (0.57) | CDK1KDRCDK2NUAK1STK16 | |
| SCHEMBL4058944 | 0.83 | CA2 (0.57) | CA2CA1CA9CDK1KDR | |
| SCHEMBL13898374 | 0.83 | IGF1R (0.58) | CDK1KDRCDK2NUAK1STK16 | |
| SCHEMBL4061169 | 0.82 | CA2 (0.70) | CA2CA1CA9CDK1KDR | |
| SCHEMBL4063568 | 0.82 | CA2 (0.58) | CA2CDK1KDRCDK2CDK9 | |
| SCHEMBL3873057 | 0.82 | CA2 (0.60) | CA2CA1CA9CDK1KDR | |
| SCHEMBL3873050 | 0.81 | STK17A (0.73) | CA2CA1CA9CDK1KDR | |
| SCHEMBL3865620 | 0.81 | STK17A (0.68) | CA2CA1CA9CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1717396-A | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2006-01-04 | — | — | CN | claimed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | claimed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | claimed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| CN-1717396-A | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | CA2 3940/4885CA1 4875/4885CA9 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.